The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.

Dr Erica Schwartz, nominated to lead the US Centers for Disease Control and Prevention, is highly qualified, according to ...

4P004 represents a first-in-class application of GLP-1 receptor agonism in the intra-articular space, specifically targeting patients with knee osteoarthritis and synovitis who have failed multiple ...

Gabapentinoids are associated with an increased risk for drug poisoning, particularly in the short-term after initiation, according to a study published online ...

Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...

Ravulizumab achieves statistically significant and clinically meaningful proteinuria reduction in adults with IgA nephropathy by week 34. Topline data were announced from a phase 3 trial evaluating ...

No increase seen in incidence of major bleeding, adverse events, or serious adverse events compared with placebo.

Older adults with adenoma at prior colonoscopy more likely to experience CRC but risk exceeded by competing risks for non-CRC death.

Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.

Treatment with daraxonrasib significantly improves progression free survival and overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma. Topline results were ...

The US Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies. Peptides are small chains of amino acids ...

Supported by the phase 3 ALLEGORY trial, the application moves obinutuzumab closer to becoming a new standard for patients with active, autoantibody-positive SLE.